[1] |
Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC 207 for multidrug-resistant tuberculosis. Engl J Med, 2009, 360(23): 2397-2405. doi:10.1056/NEJMoa0808427.
doi: 10.1056/NEJMoa0808427
URL
|
[2] |
Diacon AH, Pyre A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med, 2014, 371(8): 723-732. doi:10.1056/NEJMoal313865.
doi: 10.1056/NEJMoal313865
URL
|
[3] |
Gao M, Gao J, Xie L, et al. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR mad XDR TB in China: a multicentre study. Clin Microbiol Infect, 2021, 27 (4): 597-602. doi:10.1016/j.cmi.2020.06.004.
doi: 10.1016/j.cmi.2020.06.004
URL
|
[4] |
World Health Organization. Report of the guideline development group meeting on the use of bedaquiline in the treatment of multidrug resistant tuberculosis:a review of available evidence (2016). Geneva: World Health Organization, 2016.
|
[5] |
World Health Organization. Meeting report of the WHO expert consultation on the definition of extensively drug-resis-tant tuberculosis, 27-29 October 2020. Geneva: World Health Organization, 2021.
|
[6] |
中国防痨协会. 耐药结核病化学治疗指南(2019年简版). 中国防痨杂志, 2019, 41(10):1025-1073. doi:10.3969/j.issn.1000-6621.2019.10.001.
doi: 10.3969/j.issn.1000-6621.2019.10.001
|
[7] |
中国防痨协会. 耐药结核病化学治疗指南(2015). 中国防痨杂志, 2015, 37(5): 421-469. doi:10.3969/J.issn.1000-6521.2015.05.001.
doi: 10.3969/J.issn.1000-6521.2015.05.001
|
[8] |
World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization, 2019.
|
[9] |
Groschel MI, Seddon JA, Prabowo SA, et al. European gui-dance on drug-resistant tuberculosis in children and adolescents. Lancet Child Adolesc Health, 2020, 4(1): 9-11. doi:10.1016/s2352-4642(19)30332-3.
doi: 10.1016/s2352-4642(19)30332-3
URL
|
[10] |
中华医学会结核病学分会. 抗结核新药贝达喹啉临床应用专家共识(2020年更新版). 中华结核和呼吸杂志, 2021, 44(2): 81-87. doi:10.3760/cma.j.cn112147-20200714-00805.
doi: 10.3760/cma.j.cn112147-20200714
|
[11] |
U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE)[EB/OL]. [2021-01-21]. https://ctep.cancer.Gov/protoco1development/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf.
|
[12] |
Pyre AS, Diacon AH, Tang SJ, et al. Bedaquiline in the treatnlent of multidrug-and extensively drug-resistant tuberculosis. Eur Respir J, 2016, 47(2): 564-574. doi:10.1183/13993003.007242015.
doi: 10.1183/13993003.007242015
URL
|
[13] |
Haagsma AC, Podasca I, Koul A, et al. Probing the interaction of the diarylquinoline TMC 207 with its target mycobacterial ATP synthase. PLoS One, 2011, 6(8): e23575. doi:10.1371/10urnal.pone.0023575.
doi: 10.1371/10urnal.pone.0023575
|
[14] |
时正雨, 吴桂辉, 黄涛, 等. 含贝达喹啉方案治疗耐多药/广泛耐药结核病的24周单组观察性研究. 中国防痨杂志, 2021, 43 (5): 487-494. doi:10.3969/j.issn.1000-6621.2021.05.014.
doi: 10.3969/j.issn.1000-6621.2021.05.014
|
[15] |
Borisov SE, Dheda K, Enwerem M, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR and XDR TB: a multicentre study. Eur Respir J, 2017, 49(5): 1700387. doi:10.1183/13993003.00387-2017.
doi: 10.1183/13993003.00387-2017
|
[16] |
Seddon JA, Hesseling AC, Godfrey-Faussett P, et al. High treatment success in children treated for multidrug-resistant tuberculosis: an observational cohort study. Thorax, 2014, 69(5):458-464. doi:10.1136/thoraxjnl-2013-203900.
doi: 10.1136/thoraxjnl-2013-203900
pmid: 24064441
|
[17] |
Seddon JA, Thee S, Jacobs K, et al. Hearing loss in children treated for multidrug-resistant tuberculosis. J Infect, 2013, 66(4):320-329. doi:10.1016/j.jinf.2012.09.002.
doi: 10.1016/j.jinf.2012.09.002
pmid: 22960077
|
[18] |
中华医学会结核病学分会. 中国耐多药和利福平耐药结核病治疗专家共识(2019年版). 中华结核和呼吸杂志, 2019, 42(10): 733-749. doi:10.3760/cma.j.issn.1001-0939.2019.10.006.
doi: 10.3760/cma.j.issn.1001-0939.2019.10.006
|
[19] |
World Health Organization. WHO consolidated guidelines on tuberculosis: Module 5: Management of tuberculosis in children and adolescents. Geneva: World Health Organization, 2022.
|
[20] |
World Health Organization. WHO operational handbook on tuberculosis: Module 5: Management of tuberculosis in children and adolescents. Geneva: World Health Organization, 2022.
|
[21] |
Achar J, Hewison C, Cavalheiro AP, et al. Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis. Emerg Infect Dis, 2017, 23(10): 1711-1713. doi:10.3201/eid2310.170303.
doi: 10.3201/eid2310.170303
URL
|
[22] |
Solodovnikova V, Kumar AMV, Hurevich H, et al. Effectiveness and safety of delamanid- or bedaquiline-containing regi-mens among children and adolescents with multidrug resistant or extensively drug resistant tuberculosis: A nationwide study from Belarus, 2015-19. Monaldi Arch Chest Dis, 2021, 91(1). doi:10.4081/monaldi.2021.1646.
doi: 10.4081/monaldi.2021.1646
|
[23] |
Moodliar R, Aksenova V, Frias MVG, et al. Bedaquiline for multidrug-resistant TB in paediatric patients. Int J Tuberc Lung Dis, 2021, 25(9): 716-724. doi:10.5588/ijtld.21.0022.
doi: 10.5588/ijtld.21.0022
pmid: 34802493
|